semaj83/ctmatch_classification huggingface dataset:
Patient description: The patient is a 17-year-old boy complaining of severe migratory pain in the right lower quadrant of his abdomen that started four days ago. The pain is accompanied by nausea and vomiting. He was febrile with tenderness, rebound tenderness and guarding on palpation. His WBC was elevated with dominant neutrophils. CT scan showed evidence of acute perforated appendicitis with free fluid in the pelvis. Diagnostic laparoscopy revealed phlegmon with no other abdominal abnormalities. He is now a candidate for emergent laparoscopic appendectomy under general anesthesia.

Clinical trial eligibility criteria: eligible ages (years): 0.0-999.0,  Colorectal Neoplasm All patients greater than 18 years old who have had a prior resection of colorectal cancer and are suspected of having recurrent disease. Rising serum CEA levels greater than 6 on two successive tests. Resectable residual or recurrent disease. Patients in the occult arm (Arm 1) must have no visible residual disease in the abdomen at the time of the last surgical exploration. In addition, there must be no imageable definitive site of recurrent disease using conventional imaging modalities including; CT scan of chest/ abdomen/ pelvis with contrast, MRI scan, and chest x-ray. Patients in arm 2 may have a single site of recurrent or metastatic disease which is resectable but in whom additional sites of disease are not known and no imageable disease other than a solitary site of potentially resectable disease is identified. Patients must have an ECOG performance status of 0-1. Patients must be willing to return to NIH for follow-up. Patients must be able to provide informed consent as demonstrated by the signed consent. Patients must be 2 or more months from abdominal or thoracic surgery. No patients with medical contraindication to abdominal exploration. No patients with recurrent disease detected by conventional imaging studies as outlined above. Metastatic disease localized outside of the abdominal cavity by conventional imaging studies as outlined above. Patients must weigh less than 136 kgs. which is the weight limit for the scanner tables. No patients with previous injection of murine monoclonal antibodies: Human anti-mouse assay (HAMA) will be performed in patients with prior history of receiving murine monoclonal antibodies. No patients that are pregnant or breast feeding. Patients who are HIV + will be excluded
Patient description: The patient is a 17-year-old boy complaining of severe migratory pain in the right lower quadrant of his abdomen that started four days ago. The pain is accompanied by nausea and vomiting. He was febrile with tenderness, rebound tenderness and guarding on palpation. His WBC was elevated with dominant neutrophils. CT scan showed evidence of acute perforated appendicitis with free fluid in the pelvis. Diagnostic laparoscopy revealed phlegmon with no other abdominal abnormalities. He is now a candidate for emergent laparoscopic appendectomy under general anesthesia.

Clinical trial eligibility criteria: eligible ages (years): 16.0-120.0,  Fatigue Lung Cancer Nausea and Vomiting Pain Pulmonary Complications Quality of Life Histologically or cytologically proven non-small cell lung cancer Squamous cell lung cancer Large cell lung cancer Adenocarcinoma lung cancer Mixture of above Locally advanced disease for which the patient declined aggressive treatment or that is unsuitable for aggressive curative treatment due to at least one of the following: Performance status of ECOG 2 or 3 Otherwise unexplained weight loss greater than 10% in the last 6 months Bulky disease that cannot be irradiated safely to high doses Inability to tolerate chemotherapy Cytologically positive pleural effusion OR Clinically or radiologically proven metastatic disease for which palliative chemotherapy is not planned in the first 38 days after radiotherapy No more than one brain metastasis allowed One of the following symptoms identified as the index symptom: Loss of appetite Nausea Vomiting Cough Coughing up blood Chest pain Shortness of breath Difficulty swallowing Fatigue Must have symptoms related to intrathoracic lung cancer that are amenable to radiation palliation Age: 16 and over Performance status: ECOG 0-3 Life expectancy: Greater than 3 months Hematopoietic: Not specified Hepatic: Not specified Renal: Not specified Other: Fluent in English or French No loss of sight or other inability to complete questionnaires or diary Not pregnant No concurrent terminal illness No other active malignancy that is causing symptoms or is expected to progress in the next 3 months PRIOR Biologic therapy: Not specified Chemotherapy: At least 30 days since prior chemotherapy and failed No planned chemotherapy within 38 days after study treatment Endocrine therapy: Not specified Radiotherapy: No planned laser therapy within 38 days after study treatment Surgery: At least 30 days since prior surgery and failed Other: No planned photodynamic therapy or sclerotherapy within 38 days after study treatment
Patient description: The patient is a 17-year-old boy complaining of severe migratory pain in the right lower quadrant of his abdomen that started four days ago. The pain is accompanied by nausea and vomiting. He was febrile with tenderness, rebound tenderness and guarding on palpation. His WBC was elevated with dominant neutrophils. CT scan showed evidence of acute perforated appendicitis with free fluid in the pelvis. Diagnostic laparoscopy revealed phlegmon with no other abdominal abnormalities. He is now a candidate for emergent laparoscopic appendectomy under general anesthesia.

Clinical trial eligibility criteria: eligible ages (years): 0.0-999.0,  Pancreatic Cancer Pancreatic Neoplasm Patients must have regionally confined histologically or cytologically proven adenocarcinoma of the pancreas or Ampulla of Vater. Tumors must overexpress HER2 as demonstrated by greater than or equal to 2+ immunohistochemical staining of the biopsy specimen. Patients must sign an informed consent. Patients must have an ECOG performance status of less than or equal to 2. Patients should have a serum creatinine less than 1.5 mg/dl or creatinine clearance greater than 60 ml/hr; SGOT and SGPT less than 4 times the upper limit of normal. Patients must have an ANC greater than 2000/mm(3) and platelets greater than 100,000/mm(3). Patients must be at least 18 years of age. Patients of all racial and gender groups will be included. Patients must not have received any prior gemcitabine, radiotherapy, or Herceptin therapy for pancreatic cancer. Patients cannot receive concurrent hormonal or immunotherapy treatment for pancreatic cancer. Patients cannot receive any anti-tumor therapy within 30 days of protocol and must have recovered from any prior treatment related toxicity. Patients must not have evidence of distant metastases (e.g., peritoneal, carcinomatosis, liver metastases). No concurrent second malignancy other than non-melanoma skin cancer or cervical carcinoma in situ. Must not have medical conditions that preclude undergoing surgery or receiving therapy or follow up, or have psychiatric disease which would prevent adequate informed consent or render receiving this therapy unsafe. No patients with an LV ejection fraction less than the lower limit of normal as determined at the Clinical Center, NIH. Women must not be pregnant or nursing due to the unknown effects of this therapy on the unborn or nursing child. Must not have received prior abdominal or pelvic radiation. Must not have recent myocardial infarction (less than 6 months prior), unstable angina, or congestive heart failure (NYHA class III or IV). Must not have active diseases which make the patient more susceptible to infection, including but not limited to AIDS, hepatitis, history of autoimmune disorders, because the experimental treatment being evaluated in this protocol may be unsafe in the absence of an intact immune system
Patient description: The patient is a 17-year-old boy complaining of severe migratory pain in the right lower quadrant of his abdomen that started four days ago. The pain is accompanied by nausea and vomiting. He was febrile with tenderness, rebound tenderness and guarding on palpation. His WBC was elevated with dominant neutrophils. CT scan showed evidence of acute perforated appendicitis with free fluid in the pelvis. Diagnostic laparoscopy revealed phlegmon with no other abdominal abnormalities. He is now a candidate for emergent laparoscopic appendectomy under general anesthesia.

Clinical trial eligibility criteria: eligible ages (years): 0.0-20.0,  Recurrent Abdominal Pain Patients with Recurrent Abdominal Pain (RAP), as defined by the Apley's classic definition of paroxysmal abdominal pain occurring in children between the ages of 4 and 16 years that persists for more than three months, with a frequency of three or more episodes of abdominal pain over a three month interval Patients with Irritable Bowel Syndrome (IBS) defined by a similar pattern of abdominal pain as for RAP patients, and relieved by defecation and/or associated with altered bowel habits and/or stool consistency
Patient description: The patient is a 17-year-old boy complaining of severe migratory pain in the right lower quadrant of his abdomen that started four days ago. The pain is accompanied by nausea and vomiting. He was febrile with tenderness, rebound tenderness and guarding on palpation. His WBC was elevated with dominant neutrophils. CT scan showed evidence of acute perforated appendicitis with free fluid in the pelvis. Diagnostic laparoscopy revealed phlegmon with no other abdominal abnormalities. He is now a candidate for emergent laparoscopic appendectomy under general anesthesia.

Clinical trial eligibility criteria: eligible ages (years): 0.0-21.0,  Mastocytosis Children with tissue-diagnosed pediatric-onset mastocytosis formerly enrolled in protocols 90-I-0120, and 93-I-0136 or per physician referral with more severe disease as indicated by one of the following parameters Hepatomegaly or splenomegaly Diffuse cutaneous mastocytosis History of gastrointestinal bleeding or peptic ulcer disease Bone marrow biopsy with abnormal numbers or shaped mast cells or abnormal flow cytometry Serum tryptase greater than 20ng/ml Hematologic abnormalities such as an increase WBC, thrombocytosis, and/or an increase in PT and/or PTT Age birth to 21.0 years of age at the time of entry into the protocol Diagnosis of mastocytosis by skin examination or histologic evidence in a skin or bone marrow biopsy Subject has a primary medical care provider outside the NIH  Age greater than or equal to 21.0 years No primary care physician Has AIDS or is HIV Positive
Patient description: The patient is a 17-year-old boy complaining of severe migratory pain in the right lower quadrant of his abdomen that started four days ago. The pain is accompanied by nausea and vomiting. He was febrile with tenderness, rebound tenderness and guarding on palpation. His WBC was elevated with dominant neutrophils. CT scan showed evidence of acute perforated appendicitis with free fluid in the pelvis. Diagnostic laparoscopy revealed phlegmon with no other abdominal abnormalities. He is now a candidate for emergent laparoscopic appendectomy under general anesthesia.

Clinical trial eligibility criteria: eligible ages (years): 0.0-999.0,  Healthy Tooth Extraction Subjects will be a convenience sample selected from the pool of 500 new patients screened annually for acute pain studies. and  will be applied to result in a homogeneous population of subjects with respect to the surgical difficulty of the tooth being extracted, a single lower right third molar
Patient description: The patient is a 17-year-old boy complaining of severe migratory pain in the right lower quadrant of his abdomen that started four days ago. The pain is accompanied by nausea and vomiting. He was febrile with tenderness, rebound tenderness and guarding on palpation. His WBC was elevated with dominant neutrophils. CT scan showed evidence of acute perforated appendicitis with free fluid in the pelvis. Diagnostic laparoscopy revealed phlegmon with no other abdominal abnormalities. He is now a candidate for emergent laparoscopic appendectomy under general anesthesia.

Clinical trial eligibility criteria: eligible ages (years): 12.0-17.0,  Vomiting Cycle 1: Participant is to be treated with an emetogenic chemotherapy regimen that includes either cisplatin, cyclophosphamide, or carboplatin, for a documented malignancy. OR Participant did not tolerate a previously administered chemotherapy regimen, for a documented malignancy, secondary to nausea and/or vomiting that is planned to be repeated Cycle 1: Participant has Karnofsky score ≥60 Cycle 1: Participant has a predicted life expectancy of ≥3 months  Cycle 1: Participant will receive stem cell rescue therapy in conjunction with course of chemotherapy
Patient description: The patient is a 17-year-old boy complaining of severe migratory pain in the right lower quadrant of his abdomen that started four days ago. The pain is accompanied by nausea and vomiting. He was febrile with tenderness, rebound tenderness and guarding on palpation. His WBC was elevated with dominant neutrophils. CT scan showed evidence of acute perforated appendicitis with free fluid in the pelvis. Diagnostic laparoscopy revealed phlegmon with no other abdominal abnormalities. He is now a candidate for emergent laparoscopic appendectomy under general anesthesia.

Clinical trial eligibility criteria: eligible ages (years): 0.0-999.0,  Granulomatous Disease Chronic   The recipient fulfills by study design the The patient however, would be considered ineligible for the study only If his donor is unable to participate. DONOR Pregnant or lactating Donor unfit to receive G-CSF and undergo apheresis. (Uncontrolled hypertension, history of congestive heart failure or unstable angina, thrombocytopenia) HIV positive
Patient description: The patient is a 17-year-old boy complaining of severe migratory pain in the right lower quadrant of his abdomen that started four days ago. The pain is accompanied by nausea and vomiting. He was febrile with tenderness, rebound tenderness and guarding on palpation. His WBC was elevated with dominant neutrophils. CT scan showed evidence of acute perforated appendicitis with free fluid in the pelvis. Diagnostic laparoscopy revealed phlegmon with no other abdominal abnormalities. He is now a candidate for emergent laparoscopic appendectomy under general anesthesia.

Clinical trial eligibility criteria: eligible ages (years): 0.0-17.0,  Anesthesia Male and female subjects from birth up to 17 years of age who will be scheduled for surgery under general anesthesia  Subjects whose parent(s) or legal guardian(s) are not willing to give written consent and where applicable, subjects who have not given appropriate assent to participate in the trial will not be allowed to enter
Patient description: The patient is a 17-year-old boy complaining of severe migratory pain in the right lower quadrant of his abdomen that started four days ago. The pain is accompanied by nausea and vomiting. He was febrile with tenderness, rebound tenderness and guarding on palpation. His WBC was elevated with dominant neutrophils. CT scan showed evidence of acute perforated appendicitis with free fluid in the pelvis. Diagnostic laparoscopy revealed phlegmon with no other abdominal abnormalities. He is now a candidate for emergent laparoscopic appendectomy under general anesthesia.

Clinical trial eligibility criteria: eligible ages (years): 18.0-999.0,  Appendicitis Before CT scanning Clinical suspicion of appendicitis Age more than 18 years  Clinical signs of generalized peritonitis Previous take of antibiotics within the 5 days preceding the presentation Allergy or intolerance to lactamases and/or clavulanate potassium Corticosteroid or anticoagulant therapy Patient with a known inflammatory bowel disease (Crohn's disease or ulcerative colitis) Pregnant women Patient with iode allergy Renal insufficiency (creatinine > 200 ) CT scanning Appendix diameter > 6 mm Appendix non visualised
Patient description: The patient is a 17-year-old boy complaining of severe migratory pain in the right lower quadrant of his abdomen that started four days ago. The pain is accompanied by nausea and vomiting. He was febrile with tenderness, rebound tenderness and guarding on palpation. His WBC was elevated with dominant neutrophils. CT scan showed evidence of acute perforated appendicitis with free fluid in the pelvis. Diagnostic laparoscopy revealed phlegmon with no other abdominal abnormalities. He is now a candidate for emergent laparoscopic appendectomy under general anesthesia.

Clinical trial eligibility criteria: eligible ages (years): 0.083-18.0,  Perforated Appendicitis All patients under 18 years of age found to have perforated appendicitis at the time of operation for appendicitis and whose parents give informed permission will be included in the study  Patients with a normal or non-perforated appendix at the time of appendectomy, those without parental permission, or those with a documented allergy to any of the antibiotics used in either regimen will be excluded from the study. Patients 18 years or older will not be included in the study
Patient description: The patient is a 17-year-old boy complaining of severe migratory pain in the right lower quadrant of his abdomen that started four days ago. The pain is accompanied by nausea and vomiting. He was febrile with tenderness, rebound tenderness and guarding on palpation. His WBC was elevated with dominant neutrophils. CT scan showed evidence of acute perforated appendicitis with free fluid in the pelvis. Diagnostic laparoscopy revealed phlegmon with no other abdominal abnormalities. He is now a candidate for emergent laparoscopic appendectomy under general anesthesia.

Clinical trial eligibility criteria: eligible ages (years): 18.0-999.0,  Non Small Cell Lung Cancer • Histologically or cytologically confirmed NSCLC Stage IIIB unsuitable for radical radiation (eg. with cytologically proven malignant effusion) or stage IV disease as defined by the AJCC (see appendix 1) Karnofsky performance status 70% or higher (see appendix 2) Presence of at least one bidimensionally or unidimensionally measurable, non-CNS, indicator lesion defined by radiologic study or physical examination No previous chemotherapy for advanced disease. Prior neoadjuvant or adjuvant chemotherapy, or chemotherapy given concurrently with radiotherapy for non-metastatic disease, is allowed if the last dose was given 6 months or more before study entry Patients with recurrent disease after primary surgery and/or radiotherapy will be eligible For patients with previous radiotherapy, the indicator lesion(s) must not be within previous radiation field. The last dose of radiotherapy should be at least 3 weeks prior to study entry. The total radiotherapy received should not be more than 30% of the bone marrow Screening laboratory WBC count > 3500/microl Neutrophils > 2000/microl Platelet count > 100,000/microl Hemoglobin > 9 g/dl (transfusion allowed) Serum creatinine < 133 micromol/l, or Creatinine clearance > 30 ml/min, based on the Cockcroft formula (see section 5.1.1) Bilirubin < 1.5 x upper limit of normal ALT/AST < 2 x upper limit of normal if liver metastases are absent < 5 x upper limit of normal if liver metastases are present Aged 18 years and above Life expectancy > 3 months  • Patients with only evaluable disease Active uncontrolled infection Pregnant or lactating women Females of childbearing potential who are unwilling to avoid pregnancy, for the duration of the study Presence of any underlying medical conditions which in the investigators opinion would make the patient unsuitable for treatment Concomitant malignancies or previous malignancies other than NSCLC within the last 5 years, with the exception of adequately treated basal or squamous cell carcinoma of the skin, carcinoma-in-situ of the cervix, or stage A low grade prostate cancer Patients with CNS and/or leptomeningeal metastases; unless asymptomatic and not receiving corticosteriod therapy
Patient description: The patient is a 17-year-old boy complaining of severe migratory pain in the right lower quadrant of his abdomen that started four days ago. The pain is accompanied by nausea and vomiting. He was febrile with tenderness, rebound tenderness and guarding on palpation. His WBC was elevated with dominant neutrophils. CT scan showed evidence of acute perforated appendicitis with free fluid in the pelvis. Diagnostic laparoscopy revealed phlegmon with no other abdominal abnormalities. He is now a candidate for emergent laparoscopic appendectomy under general anesthesia.

Clinical trial eligibility criteria: eligible ages (years): 0.0-999.0,  Prostate Cancer Histologically confirmed adenocarcinoma of the prostate Stage I-III disease (T1-T3, N0, M0) No clinical or radiographic evidence of metastasis If prostate-specific antigen (PSA) ≥ 10.0 ng/mL and Gleason score is 7, a radioisotope bone scan must show no evidence of metastasis No evidence of lymphatic or visceral metastases of the abdomen or pelvis on CT scan or MRI PSA ≤ 20 ng/mL Gleason score ≤ 7 (if stage T3 , score must be < 7) Performance status Not specified Life expectancy More than 10 years Hematopoietic Not specified Hepatic
Patient description: The patient is a 17-year-old boy complaining of severe migratory pain in the right lower quadrant of his abdomen that started four days ago. The pain is accompanied by nausea and vomiting. He was febrile with tenderness, rebound tenderness and guarding on palpation. His WBC was elevated with dominant neutrophils. CT scan showed evidence of acute perforated appendicitis with free fluid in the pelvis. Diagnostic laparoscopy revealed phlegmon with no other abdominal abnormalities. He is now a candidate for emergent laparoscopic appendectomy under general anesthesia.

Clinical trial eligibility criteria: eligible ages (years): 0.5-2.5,  Diarrhea Pneumonia Acute Respiratory Tract Infection Children in the age group 6-30 months Either sex  Refused consent Likely to move out of study area within the next four months Urgent admission to hospital on the enrollment day Had received massive dose of vitamin A within the two months before enrollment
Patient description: The patient is a 17-year-old boy complaining of severe migratory pain in the right lower quadrant of his abdomen that started four days ago. The pain is accompanied by nausea and vomiting. He was febrile with tenderness, rebound tenderness and guarding on palpation. His WBC was elevated with dominant neutrophils. CT scan showed evidence of acute perforated appendicitis with free fluid in the pelvis. Diagnostic laparoscopy revealed phlegmon with no other abdominal abnormalities. He is now a candidate for emergent laparoscopic appendectomy under general anesthesia.

Clinical trial eligibility criteria: eligible ages (years): 18.0-80.0,  Surgical Wound Infection Surgery, Colon Colon resection expected to last >2 and <6 hours  Bowel obstruction Fever